UCB7665

Phase 2Small molecule

UCB

UCB7665 is one of 83 small molecule programs targeting Myasthenia Gravis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myasthenia GravisActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

Myasthenia GravisPhase 2

Active, not recruiting

Immune ThrombocytopeniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Nplate

Amgen

Phase 3

8 2

Rysodeg

UCB

Phase 3

3 3

Cellcept

Roche

Phase 3

2 4

Doptelet

AAkarx

Phase 3

6 5

Vyvgart

Argenx

Phase 3

6 6

Fabhalta

Johnson & Johnson

Phase 3

—7

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

3 8

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

3 9

Tamiflu

CConrado Roberto Hoffmann Filho

Phase 3

1 10

Avlosulfon

AAlmirall, S.A.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Completed· UCB logo

UCB·Phase 2·NCT02718716·66 enrolled

Myasthenia Gravis1 trial

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Completed· UCB logo

UCB·Phase 2·NCT03052751·43 enrolled

Single Dose1 trial

A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers

Completed· UCB logo

UCB·Phase 1·NCT02220153·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for UCB7665. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UCB7665 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UCB7665. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UCB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UCB

UCB7665

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Myasthenia Gravis1 trial

Single Dose1 trial

References

Drug Info

Quick Facts

Related News